The short answer
The claim is specifically about resistance to degradation in human gastric juice, an environment that destroys most peptides within minutes. Its proline content gives a plausible structural basis. It does not mean the peptide is indefinitely stable in solution or resistant to all proteases.
Key facts
- The claim
- Stable in human gastric juice
- Structural basis
- Four prolines, three consecutive
- Why proline helps
- Proline-adjacent bonds resist most proteases
- Does not mean
- Indefinite solution stability
- Does not mean
- Resistance to every protease
- Still applies
- Chemical hydrolysis over time
What kind of stability is being claimed
Enzymatic and acidic stability in a specific environment. Gastric juice combines a pH around 1.5 to 3.5 with pepsin, and most peptides do not survive it. The claim is that BPC-157 does, which is a narrow and testable proposition rather than a general assertion of robustness.
Why the structure makes it plausible
Proteases require an extended backbone conformation at their active site, and proline prevents the backbone adopting it nearby. BPC-157 has four prolines including a run of three, which places a substantial fraction of its bonds in protease-resistant contexts. This is the same principle that Semax and Selank exploit with their Pro-Gly-Pro extensions, applied more extensively.
Research material referenced
BPC-157 5mg, third-party HPLC tested
What the claim does not cover
Chemical hydrolysis, which proceeds without enzymes and is why lyophilised storage matters. Oxidation, though the absence of cysteine and methionine largely removes that route here. And stability in other environments: resistance to pepsin at low pH does not predict resistance to a different protease in a different compartment.
Why it does not follow that oral administration works
This inference is commonly made and it does not hold. Surviving the stomach is one of three barriers to oral bioavailability. The others are enzymatic degradation in the small intestine by trypsin and chymotrypsin, and crossing the intestinal epithelium; a large, polar, charged fifteen-residue peptide is not a promising candidate for passive permeation. Gastric stability addresses the first barrier only.
Whose claim it is
The stability characterisation comes from the Zagreb group, along with most of the compound's literature. As with everything else in this category, that concentration means the finding is less independently established than its frequency of repetition suggests.
Frequently asked questions
Is BPC-157 stable?
The claim is specifically resistance to degradation in gastric juice, supported structurally by its proline content. It is not a claim of indefinite or universal stability.
Does gastric stability mean it works orally?
No. Surviving the stomach is one of three barriers; intestinal proteases and epithelial permeability are the others.
Does it still need cold storage?
Yes. Enzymatic stability says nothing about chemical hydrolysis, which is why lyophilised material is stored cold and dry.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedSikiric P et al., Stable gastric pentadecapeptide BPC 157. Curr Pharm Des 2011 (PMID 21548867)pubmed.ncbi.nlm.nih.gov
- PubMedSikiric P et al., BPC 157 in trials for IBD. Inflammopharmacology 2006 (PMID 17186181)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · BPC-157 (CID 9941957)pubchem.ncbi.nlm.nih.gov
- PubMedSikiric P et al., Fistulas Healing: Stable Gastric Pentadecapeptide BPC 157 Therapy. Curr Pharm Des 2020 (PMID 32329684)pubmed.ncbi.nlm.nih.gov
- PubMedKrivic A et al., Achilles detachment in rat and stable gastric pentadecapeptide BPC 157. J Orthop Res 2006 (PMID 16583442)pubmed.ncbi.nlm.nih.gov
- PubMedCerovecki T et al., Pentadecapeptide BPC 157 improves ligament healing in the rat. J Orthop Res 2010 (PMID 20225319)pubmed.ncbi.nlm.nih.gov
- PubMedSeiwerth S et al., BPC 157 and blood vessels. Curr Pharm Des 2014 (PMID 23782145)pubmed.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More BPC-157 (Pentadecapeptide) articles
- BPC-157 Storage, Stability and ReconstitutionProline-rich and free of cysteine and methionine, so enzymatically and chemically robust. Why gastric stability does not remove the need for cold, dry storage.
- BPC-157 Mechanism: Why It Is Described as Multi-PathwayReported effects span angiogenic signalling, growth-factor interactions and nitric oxide pathways. Why no single defining mechanism has emerged.
- BPC-157 and Blood VesselsVascular effects recur across the BPC-157 literature and offer the most plausible common thread linking its reported activity in different tissues.
- Tendon and Ligament ModelsKrivic on Achilles detachment and Cerovecki on ligament healing, both in the Journal of Orthopaedic Research. What rat models can and cannot establish.
- Growth Factor Signalling in the BPC-157 LiteratureReported interactions with growth-factor systems are part of the multi-pathway description. What that means when no receptor for the peptide is known.